NASDAQ:BPMC - Blueprint Medicines Stock Price, Forecast & News

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Blueprint Medicines Corp (NASDAQ:BPMC) issued its quarterly earnings data on Thursday, February, 13th. The biotechnology company reported ($1.35) earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($1.71) by $0.36. The biotechnology company earned $51.53 million during the quarter, compared to the consensus estimate of $26 million. Blueprint Medicines had a negative net margin of 522.75% and a negative return on equity of 72.52%. Blueprint Medicines's revenue for the quarter was up 4888.7% on a year-over-year basis. During the same quarter last year, the company earned ($1.83) earnings per share. View Blueprint Medicines' Earnings History.

Blueprint Medicines is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Blueprint Medicines.

12 brokers have issued 1 year price objectives for Blueprint Medicines' shares. Their forecasts range from $70.00 to $125.00. On average, they anticipate Blueprint Medicines' stock price to reach $104.08 in the next year. This suggests a possible upside of 55.4% from the stock's current price. View Analyst Price Targets for Blueprint Medicines.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 3 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Blueprint Medicines.

Media stories about BPMC stock have trended very negative this week, according to InfoTrie Sentiment Analysis. The research firm rates the sentiment of media coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Blueprint Medicines earned a news sentiment score of -3.4 on InfoTrie's scale. They also assigned headlines about the biotechnology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for Blueprint Medicines.

Some companies that are related to Blueprint Medicines include Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Bausch Health Companies (BHC), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Reata Pharmaceuticals (RETA) and Ascendis Pharma A/S (ASND).

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), Micron Technology (MU), Canopy Growth (CGC), Nektar Therapeutics (NKTR), AbbVie (ABBV), Ionis Pharmaceuticals (IONS), Stratasys (SSYS), STMicroelectronics (STM), Global Blood Therapeutics (GBT) and Intercept Pharmaceuticals (ICPT).

(BPMC) raised $115 million in an initial public offering on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company acted as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Blueprint Medicines' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), Cadian Capital Management LP (4.00%), State Street Corp (3.81%), Alliancebernstein L.P. (2.08%), Westfield Capital Management Co. LP (1.57%) and Eagle Asset Management Inc. (1.55%). Company insiders that own Blueprint Medicines stock include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View Institutional Ownership Trends for Blueprint Medicines.

BPMC stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Pictet Asset Management Ltd., Perceptive Advisors LLC, BVF Inc. IL, Victory Capital Management Inc., Westfield Capital Management Co. LP, Victory Capital Management Inc. and Spark Investment Management LLC. Company insiders that have sold Blueprint Medicines company stock in the last year include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View Insider Buying and Selling for Blueprint Medicines.

BPMC stock was bought by a variety of institutional investors in the last quarter, including Cadian Capital Management LP, Point72 Asset Management L.P., Candriam Luxembourg S.C.A., Credit Suisse AG, Barclays PLC, Alliancebernstein L.P., Jane Street Group LLC and Sectoral Asset Management Inc. View Insider Buying and Selling for Blueprint Medicines.

Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BPMC stock can currently be purchased for approximately $66.96.

Blueprint Medicines has a market capitalization of $3.62 billion and generates $66.51 million in revenue each year. The biotechnology company earns $-347,690,000.00 in net income (profit) each year or ($7.27) on an earnings per share basis. Blueprint Medicines employs 217 workers across the globe.View Additional Information About Blueprint Medicines.

The official website for Blueprint Medicines is http://www.blueprintmedicines.com/.

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]